Novo Nordisk Ends Wegovy Partnership with Hims & Hers
Novo Nordisk has severed its partnership with Hims & Hers due to concerns over the sale of unapproved Wegovy versions.This decisive move, announced Monday, saw Hims & Hers shares tumble, reflecting anxieties about the potential impact on patient safety and market regulations. Novo Nordisk cited violations related to compounding and deceptive marketing as the main drivers for the split. Explore how the end of the collaboration has sparked debate between the two companies, with Hims & Hers’ CEO disputing the claims. News Directory 3 has the breaking details, including Novo Nordisk’s plans to combat illegal compounding through legal action and FDA collaboration, and the legal risks now facing Hims & Hers. Discover what’s next …
Novo Nordisk Ends Hims & Hers Partnership Over Wegovy Concerns
Updated June 24, 2025
Novo Nordisk, the maker of the popular weight loss drug Wegovy, is ending its partnership with telehealth company Hims & Hers. the decision, announced Monday, stems from Novo Nordisk’s worries about Hims & Hers promoting and selling cheaper, unapproved versions of Wegovy.
the news impacted both companies’ stock prices. Hims & Hers shares plummeted more than 34%, while Novo Nordisk’s stock dipped over 5%.
The collaboration, initiated in April, aimed too broaden access to Wegovy thru telehealth platforms after supply shortages eased. Though, the end of the shortage also restricted compounding pharmacies from producing cheaper versions of the drug, with limited exceptions.
Novo Nordisk alleges that Hims & Hers violated regulations by engaging in mass sales of compounded drugs under the guise of personalization and using deceptive marketing practices that endanger patient safety. The company is taking a firm stance on patient safety regarding the weight loss drug.
“We expected that the efforts towards compounding personalization would diminish over time. when we didn’t see that, we had to make a choice on behalf of patients,” said Dave Moore, Novo Nordisk’s executive vice president of U.S. operations.
Hims & Hers CEO Andrew Dudum countered with a statement on X, expressing disappointment and accusing Novo Nordisk of misleading the public. He claimed Novo Nordisk pressured Hims & Hers to prioritize Wegovy prescriptions nonetheless of clinical suitability, adding that his company would not compromise its platform’s integrity.
“We will not compromise the integrity of our platform to appease a third party or preserve a collaboration,” Dudum said.
Citi analyst Daniel Grosslight noted the end of the partnership substantially increases Hims & Hers’ legal risk.He expressed surprise that the initial agreement lacked provisions to limit Hims & Hers’ compounding activities.
During FDA-declared drug shortages, compounding pharmacies can legally produce versions of brand-name medications. They can also do so when medically necesary for individual patients. However, drug manufacturers and some experts have voiced concerns about compounded drugs due to the lack of FDA approval.
Novo Nordisk intends to continue offering Wegovy through telehealth providers that share its commitment to safe and effective medical treatment. The company also plans to address illegal compounding through legal channels and engagement with the FDA. An examination by novo Nordisk revealed that active ingredients in Wegovy knock-offs are sourced from uninspected or quality-violating suppliers in China.
What’s next
Novo Nordisk plans to actively pursue legal avenues and collaborate with the FDA to curb the illegal compounding and sale of unapproved versions of its Wegovy drug.